Document Detail


Treatment and prophylaxis of invasive candidiasis.
MedLine Citation:
PMID:  23177800     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Invasive candidiasis (IC) is a leading cause of morbidity and mortality in preterm infants. Even if successfully treated, IC can cause significant neurodevelopmental impairment. Preterm infants are at increased risk for hematogenous Candida meningoencephalitis owing to increased permeability of the blood-brain barrier, so antifungal treatment should have adequate central nervous system penetration. Amphotericin B deoxycholate, lipid preparations of amphotericin B, fluconazole, and micafungin are first-line treatments of IC. Fluconazole prophylaxis reduces the incidence of IC in extremely premature infants, but its safety has not been established for this indication, and as yet, the product has not been shown to reduce mortality in neonates. Targeted prophylaxis may have a role in reducing the burden of disease in this vulnerable population.
Authors:
Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Seminars in perinatology     Volume:  36     ISSN:  1558-075X     ISO Abbreviation:  Semin. Perinatol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-26     Completed Date:  2013-05-24     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  7801132     Medline TA:  Semin Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  416-23     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotic Prophylaxis / methods*,  statistics & numerical data
Antifungal Agents* / classification,  therapeutic use
Blood-Brain Barrier / drug effects,  physiopathology
Candida* / drug effects,  isolation & purification,  pathogenicity
Candidiasis, Invasive* / drug therapy,  microbiology,  mortality,  physiopathology
Catheter-Related Infections / drug therapy,  microbiology,  mortality,  physiopathology
Central Nervous System / growth & development
Child Development
Cross Infection / drug therapy,  microbiology,  mortality,  physiopathology
Humans
Incidence
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases* / drug therapy,  microbiology,  mortality,  physiopathology
Meningoencephalitis* / drug therapy,  microbiology,  mortality,  physiopathology
Randomized Controlled Trials as Topic
Grant Support
ID/Acronym/Agency:
1K24HD058735-01/HD/NICHD NIH HHS; 1R01FD003519-01/FD/FDA HHS; 1R01HD057956-02/HD/NICHD NIH HHS; 1U10-HD45962-06/HD/NICHD NIH HHS; 5T32HD043029-09/HD/NICHD NIH HHS; HHSN275201000002I//PHS HHS; HHSN275201000003I/HD/NICHD NIH HHS; K24 HD058735/HD/NICHD NIH HHS; R01 HD057956/HD/NICHD NIH HHS; T32 HD043029/HD/NICHD NIH HHS; TL1 RR024126/RR/NCRR NIH HHS; TL1RR024126/RR/NCRR NIH HHS; U10 HD045962/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Antifungal Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk assessment in neonatal early onset sepsis.
Next Document:  Methicillin-resistant Staphylococcus aureus in the neonatal intensive care unit.